Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma

Last updated: February 13, 2018
Sponsor: Qingdao Central Hospital
Overall Status: Completed

Phase

2/3

Condition

Liver Disease

Primary Biliary Cholangitis

Liver Cancer

Treatment

N/A

Clinical Study ID

NCT01932385
QCH20130823
  • Ages 18-80
  • All Genders

Study Summary

Due to the HBV and HCV infection, about 55% hepatocellular carcinoma patients happened in China. Among them, only 10% patients can be diagnosed in early stage. Sorafenib increased PFS and OS in advanced hepatocellular carcinoma patients with liver function of Child-Pugh class A patients, but the result for Child-Pugh class B patients is unclear.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • pathological or cytological confirmed advanced hepatocellular carcinoma

  • 18 years to 80 years

  • liver function Child-Pugh class B

  • BCLC stage B or C

  • estimated life time 2 months or longer

Exclusion

Exclusion Criteria:

  • previous target therapy

  • allergy to Sorafenib

  • Uncontrolled Bleeding or diarrhea

  • eligible for locoregional treatment

Study Design

Total Participants: 86
Study Start date:
August 01, 2013
Estimated Completion Date:
July 30, 2016

Connect with a study center

  • Qingdao Central Hospital, Qingdao Cancer Hospital

    Qingdao, Shandong 266042
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.